NuVasive - NUVA Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued twelve-month price targets for NuVasive's stock. Their NUVA share price forecasts range from $44.00 to $63.00. On average, they predict the company's stock price to reach $51.62 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $52.48 at the beginning of the year. Since then, NUVA stock has decreased by 27.4% and is now trading at $38.08.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NUVA earnings forecast.

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Wednesday, November, 9th. The medical device company reported $0.54 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.54. The medical device company earned $295.30 million during the quarter, compared to analysts' expectations of $298.76 million. NuVasive had a negative net margin of 1.70% and a positive trailing twelve-month return on equity of 12.49%. NuVasive's quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 EPS.

NuVasive declared that its board has authorized a stock buyback program on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board believes its stock is undervalued.

NuVasive issued an update on its FY22 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $2.00-2.10 for the period, compared to the consensus earnings per share estimate of $2.24. The company issued revenue guidance of ~$1.2-1.213 billion, compared to the consensus revenue estimate of $1.22 billion.

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.38%), Thrivent Financial for Lutherans (4.93%), Macquarie Group Ltd. (4.47%), Dimensional Fund Advisors LP (2.58%), Channing Capital Management LLC (2.40%) and Stephens Investment Management Group LLC (1.53%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends.

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $38.08.

NuVasive (NASDAQ:NUVA) has a market capitalization of $1.99 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

The company employs 2,900 workers across the globe.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.